Agilent Technologies (Agilent Technologies) ROCE % : 18.39% (As of Jan. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Agilent Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Agilent Technologies's annualized ROCE % for the quarter that ended in Jan. 2024 was 18.39%.

Agilent Technologies ROCE % Historical Data

The historical data trend for Agilent Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agilent Technologies ROCE % Chart

Agilent Technologies Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

ROCE %

Get a 7-Day Free Trial

13.47

11.85

16.80

17.98

16.08

Agilent Technologies Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
ROCE %	Get a 7-Day Free Trial															19.71	17.71	6.92	19.56	18.39

Agilent Technologies ROCE % Calculation

Agilent Technologies's annualized ROCE % for the fiscal year that ended in Oct. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Oct. 2023 )		(A: Oct. 2022 )		(A: Oct. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Oct. 2023 )		(A: Oct. 2022 )		(A: Oct. 2023 )
	=	1434	/	( ( (10532 - 1861)	+	(10763 - 1603) )	/ 2 )
	=	1434	/	( (8671	+	9160)	/ 2 )
	=	1434	/	8915.5
	=	16.08 %

Agilent Technologies's ROCE % of for the quarter that ended in Jan. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	1700	/	( ( (10763 - 1603)	+	(10948 - 1617) )	/ 2 )
	=	1700	/	( ( 9160	+	9331 )	/ 2 )
	=	1700	/	9245.5
	=	18.39 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2024) EBIT data.

Agilent Technologies (NYSE:A) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Agilent Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Agilent Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Agilent Technologies (Agilent Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Agilent Technologies Inc (NYSE:A) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

A:Mexico 1A:Italy AG8:Germany AG8:Germany

Address

5301 Stevens Creek Boulevard, Santa Clara, CA, USA, 95051

Website

https://www.agilent.com

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab (consisting of consumables and services related to life science and applied tools), and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. and China representing the largest country concentrations.

Executives

Philip Binns	officer: Senior Vice President	5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Rodney Gonsalves	officer: V.P., Corporate Controller	5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Henrik Ancher-jensen	officer: Sr. Vice President	5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Michael R. Mcmullen	officer: CEO and President	5301 STEVENS CREEK BLVD., MS 1A-LC, SANTA CLARA CA 95051
George A Scangos	director	C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Otis W Brawley	director	5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Mikael Dolsten	director	5 GIRALDA FARMS, MADISON NJ 07940
Mala Anand	director	C/O COTIVITI HOLDINGS, INC., 115 PERIMETER CENTER PLACE, SUITE 700, ATLANTA GA 30346
Sue H. Rataj	director	C/O CABOT CORPORATION, TWO SEAPORT LANE, SUITE 1300, BOSTON MA 02210
Dow R Wilson	director	VARIAN MEDICAL SYSTEMS INC, 3100 HANSEN WAY MAIL STOP E327, PALO ALTO CA 94304
Boon Hwee Koh	director	C/O AGILENT TECHNOLOGIES, 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Heidi Fields	director	5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Hans Edgar Bishop	director	60 WEST 66TH STREET, 26A, NEW YORK NY 10023
Daniel K Podolsky	director	5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Padraig Mcdonnell	officer: Senior Vice President	5301 STEVENS CREEK BLVD, SANTA CLARA CA 95051